ESI-09 - CAS 263707-16-0
Catalog number: 263707-16-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C16H15ClN4O2
Molecular Weight:
330.77
COA:
Inquire
Targets:
Others
Description:
ESI-09 is a specific exchange protein directly activated by cAMP (EPAC) inhibitor with IC50 of 3.2 μM and 1.4 μM for EPAC1 and EPAC2, respectively, >100-fold selectivity over PKA.ESI-09 is a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells. EPAC1 plays an important role in pancreatic cancer cell migration and invasion, and thus represents a potential target for developing novel therapeutic strategies for pancreatic cancer.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
ESI-09
MSDS:
Inquire
1.Epac-inhibitors: facts and artefacts.
Rehmann H1. Sci Rep. 2013 Oct 23;3:3032. doi: 10.1038/srep03032.
cAMP is a universal second messenger. Its signalling is mediated by protein kinase A, Epac and certain types of ion channels in mammalians. cAMP signalling is involved in many physiological processes ranging from vision to the control of insulin secretion, pacemaker activity and gene transcription and therefore selective pharmacological interference is of medical interest. Whereas selective inhibitors of PKA and selective activators of Epac are well established, no inhibitors of Epac were available until recently. Here the action of four of the novel Epac inhibitors was analysed by biophysical means. ESI-05 is confirmed as a selective inhibitor of Epac2. No direct action of Brefeldin A on Epac could be demonstrated. ESI-09 and HJC0197 were found to act as chemicals with general protein denaturing properties and do not act on Epac selectively.
2.Exchange protein directly activated by cAMP plays a critical role in bacterial invasion during fatal rickettsioses.
Gong B1, Shelite T, Mei FC, Ha T, Hu Y, Xu G, Chang Q, Wakamiya M, Ksiazek TG, Boor PJ, Bouyer DH, Popov VL, Chen J, Walker DH, Cheng X. Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19615-20. doi: 10.1073/pnas.1314400110. Epub 2013 Nov 11.
Rickettsiae are responsible for some of the most devastating human infections. A high infectivity and severe illness after inhalation make some rickettsiae bioterrorism threats. We report that deletion of the exchange protein directly activated by cAMP (Epac) gene, Epac1, in mice protects them from an ordinarily lethal dose of rickettsiae. Inhibition of Epac1 suppresses bacterial adhesion and invasion. Most importantly, pharmacological inhibition of Epac1 in vivo using an Epac-specific small-molecule inhibitor, ESI-09, completely recapitulates the Epac1 knockout phenotype. ESI-09 treatment dramatically decreases the morbidity and mortality associated with fatal spotted fever rickettsiosis. Our results demonstrate that Epac1-mediated signaling represents a mechanism for host-pathogen interactions and that Epac1 is a potential target for the prevention and treatment of fatal rickettsioses.
3.Structure-Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N'-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists.
Ye N1, Zhu Y2, Chen H1, Liu Z1, Mei FC2, Wild C1, Chen H1, Cheng X2, Zhou J1. J Med Chem. 2015 Aug 13;58(15):6033-47. doi: 10.1021/acs.jmedchem.5b00635. Epub 2015 Jul 16.
Exchange proteins directly activated by cAMP (EPAC) as guanine nucleotide exchange factors mediate the effects of the pivotal second messenger cAMP, thereby regulating a wide variety of intracellular physiological and pathophysiological processes. A series of novel 2-(isoxazol-3-yl)-2-oxo-N'-phenyl-acetohydrazonoyl cyanide EPAC antagonists was synthesized and evaluated in an effort to optimize properties of the previously identified high-throughput (HTS) hit 1 (ESI-09). Structure-activity relationship (SAR) analysis led to the discovery of several more active EPAC antagonists (e.g., 22 (HJC0726), 35 (NY0123), and 47 (NY0173)) with low micromolar inhibitory activity. These inhibitors may serve as valuable pharmacological probes to facilitate our efforts in elucidating the biological functions of EPAC and developing potential novel therapeutics against human diseases. Our SAR results have also revealed that further modification at the 3-, 4-, and 5-positions of the phenyl ring as well as the 5-position of the isoxazole moiety may allow for the development of more potent EPAC antagonists.
4.cAMP controls the restoration of endothelial barrier function after thrombin-induced hyperpermeability via Rac1 activation.
Aslam M1, Tanislav C2, Troidl C1, Schulz R3, Hamm C1, Gündüz D1. Physiol Rep. 2014 Oct 24;2(10). pii: e12175. doi: 10.14814/phy2.12175. Print 2014 Oct 1.
Inflammatory mediators like thrombin disrupt endothelial adherens junctions (AJs) and barrier integrity leading to oedema formation followed by resealing of AJs and a slow recovery of the barrier function. The molecular mechanisms of this process have not yet been fully delineated. The aim of the present study was to analyse the molecular mechanism of endothelial barrier recovery and thrombin was used as model inflammatory mediator. Thrombin caused a strong increase in endothelial permeability within 10 min accompanied by loss of Rac1 but not cdc42 activity, drop in cellular cAMP contents, and a strong activation of the endothelial contractile machinery mainly via RhoA/Rock signalling. Activation of RhoA/Rock signalling precedes and is dependent upon a rise in the cytosolic Ca(2+) concentration. Inhibition of cytosolic Ca(2+) rise but not MLCK or Rock enhances the recovery of endothelial barrier function. The cellular cAMP contents increased gradually during the barrier recovery phase (30-60 min after thrombin challenge) accompanied by an increase in Rac1 activity.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 1433286-70-4 666-15

666-15
(CAS: 1433286-70-4)

666-15 is a potent and selective inhibitor of CREB-mediated gene transcription (IC50= 81 nM) with efficacious in vitro and in vivo anti-breast cancer activity w...

CAS 189003-92-7 Trelanserin

Trelanserin
(CAS: 189003-92-7)

Trelanserin is a serotonin receptor antagonist.

CAS 33089-61-1 Amitraz

Amitraz
(CAS: 33089-61-1)

Amitraz is a non-systemic acaricide and insecticide, as an antiparasitic used to control red spider mites, leaf miners and scale insects.

CAS 33620-72-3 Britannilactone

Britannilactone
(CAS: 33620-72-3)

A bioassay-guided isolation of the chloroform fraction of the I. britannica using an in vitro melanogenesis inhibition assay led to the isolation of sesquiterpe...

CAS 80321-63-7 Gynostemma Extract

Gynostemma Extract
(CAS: 80321-63-7)

Gynostemma Extract is a saponins extract derived from the Gynostemma pentaphyllum.

CAS 6386-63-6 Cloxyfonac

Cloxyfonac
(CAS: 6386-63-6)

Cloxyfonac is a plant growth regulator and a chemical transformation product.

CAS 89250-26-0 Astragalus polysaccharide

Astragalus polysaccharide
(CAS: 89250-26-0)

Astragalus polysaccharide is one kind of biological macromolecule extracted from Astragalus. It has antiviral activities.

CAS 123-99-9 1,7-Heptanedicarboxylic Acid

1,7-Heptanedicarboxylic Acid
(CAS: 123-99-9)

Azelaic acid, produced by ozone cracking of unsaturated fatty acid, could be commonly used in grease, cosmetics and pharmaceuticals.

CAS 155030-63-0 Emodepside

Emodepside
(CAS: 155030-63-0)

Emodepside, also known as PF 1022-221, a semisynthetic derivative of PF1022A, is efficacious against a variety of gastrointestinal nematodes and used as an anth...

PROTO-1
(CAS: 312951-85-2)

PROTO-1, a benzothiophene carboxamide, shows significant protection of hair cells over a broad range of neomycin concentrations, from 25 μM to 400 μM.

CAS 110314-48-2 Adolezesin

Adolezesin
(CAS: 110314-48-2)

Adozelesin is an experimental antitumor drug of the duocarmycin class. It is the first of a class of DNA-sequence-selective alkylating agents. It binds to and a...

CAS 23047-14-5 Glibenclamide potassium salt

Glibenclamide potassium salt
(CAS: 23047-14-5)

Glibenclamide potassium salt is a salt form of Glibenclamide, a KATP channel blocker used for the treatment of type 2 diabetes. Glibenclamide binds to and inhib...

CAS 50-70-4 Sorbitol

Sorbitol
(CAS: 50-70-4)

Sorbitol is a sugar alcohol and a sugar substitute.

CAS 80573-04-2 Balsalazide

Balsalazide
(CAS: 80573-04-2)

Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is a new 5-aminosalicylic acid (5-ASA) containing prodrug. It i...

EN460
(CAS: 496807-64-8)

EN460 is a small molecule inhibitor by EN460 binding to ERO1α to promote the loss of flavin adenine dinucleotide (FAD) from the holoenzyme(IC50=1.9 uM) .

CAS 39011-91-1 Oxypaeoniflorin

Oxypaeoniflorin
(CAS: 39011-91-1)

Albiflorin and Oxypaeoniflorin in rat plasma and was successfully applied to pharmacokinetic study.

CAS 98-92-0 Nicotinamide

Nicotinamide
(CAS: 98-92-0)

Nicotinamide, a water-soluble vitamin, is an active component of coenzymes NAD and NADP, and also act as an activator of sirtuins.

CAS 312-63-0 ELN 484228

ELN 484228
(CAS: 312-63-0)

ELN 484228 is an α-Synuclein blocker with activity in cellular models of α-synuclein-mediated dysfunction such as Parkinson’s Disease. Study showed that ELN4842...

CAS 61825-98-7 Imperialine

Imperialine
(CAS: 61825-98-7)

Sipeimine, a natural product isolated from Fritillaria ussuriensis., can make Kaba cholinergic induced contraction of tracheal strips of the dose-response curve...

EL-102
(CAS: 1233948-61-2)

EL102, a HIF1α inhibitor, has been found to have potential effect in restraining polymerisation of tubulin and influencing the stability of microtubule. IC50: 2...

Chemical Structure

CAS 263707-16-0 ESI-09

Quick Inquiry

Verification code

Featured Items